Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Nuvation Bio Inc (NUVB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/07/2025: NUVB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.17
1 Year Target Price $7.17
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.43% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 711.15M USD | Price to earnings Ratio - | 1Y Target Price 7.17 |
Price to earnings Ratio - | 1Y Target Price 7.17 | ||
Volume (30-day avg) 7 | Beta 1.37 | 52 Weeks Range 1.54 - 3.97 | Updated Date 07/7/2025 |
52 Weeks Range 1.54 - 3.97 | Updated Date 07/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1913.23% |
Management Effectiveness
Return on Assets (TTM) -23.33% | Return on Equity (TTM) -119.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 260886619 | Price to Sales(TTM) 64.9 |
Enterprise Value 260886619 | Price to Sales(TTM) 64.9 | ||
Enterprise Value to Revenue 23.81 | Enterprise Value to EBITDA 2.23 | Shares Outstanding 339263008 | Shares Floating 229037814 |
Shares Outstanding 339263008 | Shares Floating 229037814 | ||
Percent Insiders 19.14 | Percent Institutions 61.81 |
Upturn AI SWOT
Nuvation Bio Inc
Company Overview
History and Background
Nuvation Bio Inc. was founded in 2018 by David Hung, M.D. to focus on developing therapies that address unmet medical needs in oncology. It went public via a SPAC merger in early 2021.
Core Business Areas
- Oncology Drug Development: Focuses on the discovery and development of therapeutic candidates for various types of cancer.
Leadership and Structure
David Hung, M.D., is the founder and CEO. The company has a board of directors and a management team overseeing research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- NUV-868: A potent and selective BD2-sparing BET inhibitor being developed for advanced cancers. It is currently undergoing clinical trials. Market share is not applicable as the drug is in development. Competitors include companies developing similar BET inhibitors.
- NUV-422: A CDK2/9 inhibitor in pre-clinical development. Market share is not applicable as the drug is in development. Competitors include companies developing similar CDK inhibitors.
Market Dynamics
Industry Overview
The oncology drug development industry is highly competitive and rapidly evolving, with significant unmet needs for effective cancer treatments.
Positioning
Nuvation Bio aims to differentiate itself through its focus on specific drug targets and its experienced leadership team.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Nuvation Bio is positioned to capture a portion of this TAM by developing innovative cancer therapies.
Upturn SWOT Analysis
Strengths
- Experienced leadership team
- Potentially differentiated drug candidates
- Strong focus on oncology
Weaknesses
- Early-stage development pipeline
- High cash burn rate
- Dependence on clinical trial success
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of the pipeline through acquisitions or in-licensing
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- GILD
Competitive Landscape
Nuvation Bio competes with both large pharmaceutical companies and smaller biotech firms in the oncology space. Its success depends on the differentiation and effectiveness of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: The company's growth has been primarily in terms of expanding its pipeline and advancing its clinical programs.
Future Projections: Future growth is dependent on clinical trial success and potential regulatory approvals. Analyst estimates vary depending on the perceived likelihood of success.
Recent Initiatives: Advancing clinical trials for NUV-868 and preclinical developments for NUV-422.
Summary
Nuvation Bio is a clinical-stage company with promising drug candidates in oncology. Its strengths lie in its experienced leadership and focused approach. However, it faces risks associated with clinical trial outcomes and competition from larger players. The company needs to focus on de-risking its pipeline and securing partnerships to enhance its long-term prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Press releases
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvation Bio Inc
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 2020-08-24 | Founder, President, CEO & Chairman Dr. David T. Hung M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 273 | Website https://www.nuvationbio.com |
Full time employees 273 | Website https://www.nuvationbio.com | ||
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.